An observational study in Gastric Cancer Stage and Gastric Cancer Patients Undergoing Gastrectomy, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University — 21 open to participants now, 24 under way, 2 of them phase 3. Stomach Neoplasms · The First Affiliated Hospital with Nanjing Medical University.
Among the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one is one of 4 that started in 2025, is one of 5 observational ones, reaches primary completion later than 20 of the 23 other live ones, and was the 22nd registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →21 of the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 65–100
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 75+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 2
First in 2016; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8,000 is above the median of 278 across 792 observational studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 23 interventional studies, 222 across the 5 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
10 of the studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06939439Phase 3The First Affiliated Hospital with Nanjing Medical UniversityUsing ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | 2026-12-31 |
| NCT07351474The First Affiliated Hospital with Nanjing Medical UniversityRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy | 2026-12-25 |
| NCT07902596The First Affiliated Hospital with Nanjing Medical UniversityLymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma | 2026-12-31 |
| NCT07391826The First Affiliated Hospital with Nanjing Medical UniversityMegestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX | 2026-12-31 |
| NCT06555471The First Affiliated Hospital with Nanjing Medical UniversityA Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .
Adults with confirmed gastric cancer undergoing pre-treatment CECT will be enrolled. The AI analysis will be applied to clinically acquired images. Radiologist interpretations with and without AI support will be collected in a prespecified reader study. The reference standard will include surgical pathology, supplemented by clinical follow-up when applicable. The primary outcome is detection performance, diagnostic performance of the AI for four-class staging (e.g., accuracy and area under the receiver operating characteristic curve). Secondary outcomes include the effect of AI assistance on reader accuracy and interpretation time, inter-reader agreement, and cross-site reproducibility.
This study will enroll adult patients (≥18 years old) with a confirmed diagnosis of gastric cancer (adenocarcinoma) who have undergone contrast-enhanced CT (CECT) as part of their standard preoperative evaluation. Participants will be selected from both internal and external cohorts, with inclusion from multiple centers to assess cross-site reproducibility and generalizability of the AI model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Retrospective case-only cohort of adults with pathologically confirmed gastric cancer who underwent preoperative contrast-enhanced CT at the sponsoring institution. Existing CT images and clinical/pathology records will be used to train and test the AI model and to estimate diagnostic performance for T and N staging.
Diagnostic Test: CT scan
Independent retrospective case-only cohort from an external hospital with the same inclusion/exclusion criteria. Used solely for external validation to assess reproducibility across sites and scanners.
Diagnostic Test: CT scan
A second independent retrospective validation cohort from another institution to further test generalizability.
Diagnostic Test: CT scan
preoperative contrast-enhanced CT
Diagnostic performance of the AI model for staging
The primary outcome is the diagnostic accuracy of the AI system for four-class T staging (T1-T4) and N staging (N0-3) based on contrast-enhanced CT. The AI performance will be assessed using accuracy, area under the receiver operating characteristic curve (AUC), and micro-AUC for internal and external cohorts.
Time frame: 3 years
Reader Accuracy with AI Support
This outcome measures the accuracy of radiologists in classifying gastric cancer stagewhen aided by the AI system compared to manual classification without AI assistance. Accuracy will be compared between different radiologist experience levels.
Time frame: 3 years
Survival time
Calculate the survival time of gastric cancer patients from the point of diagnosis and treatment initiation.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital with Nanjing Medical University →